MedTrace Logo

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

NCT00490945 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2014-08-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and efficacy of VEC-162 compared to matching placebo on circadian phase shift and sleep parameters.

Conditions

  • Circadian Rhythm Sleep Disorders

Interventions

DRUG

VEC-162

Sponsors & Collaborators

Principal Investigators

  • Marlene Dressman, PhD · Vanda Pharmaceuticals Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-03-31
Completion
2005-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00490945 on ClinicalTrials.gov